Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The evidence from the monarchE trial indicates that abemaciclib with endocrine therapy significantly improves invasive disease-free survival compared to endocrine therapy alone, with a hazard ratio of 0.680. This suggests a clear clinical advantage, although the long-term benefits remain uncertain due to ongoing data collection.
Cost effectiveness
The most plausible ICER for abemaciclib with endocrine therapy is estimated at £9,164 per QALY gained, which is within the range considered acceptable by NICE, indicating marginal cost-effectiveness.
Quality of life
The document indicates that the treatment addresses significant unmet needs and improves quality of life by reducing the risk of cancer recurrence, although specific HRQoL data from validated instruments is not detailed.
Supporting Domains
Safety and Adverse Effects
The safety profile of abemaciclib is considered acceptable, with manageable adverse effects such as diarrhea. The committee concluded that the benefits outweigh the risks, although treatment discontinuations due to adverse events were noted.
Comparator Selection
The treatment was compared against the standard of care (endocrine therapy alone) in a well-defined patient population, which is appropriate for assessing its effectiveness.
Patient Population and Subgroups
The trial population is representative of the intended patient population, with specific inclusion criteria that reflect those at high risk of recurrence, enhancing generalizability to Healthcare practice.
Care Pathway Integration
The integration of abemaciclib into existing treatment pathways is feasible with minor adjustments, as it complements current adjuvant therapies without requiring extensive new infrastructure.
Resource Use and Cost Implications
The economic model suggests that while there is a notable cost burden, it is justifiable given the potential benefits and the confidential discount arrangements in place.
Evidence Quality and Robustness
The evidence is derived from a large, ongoing Phase III trial (monarchE) with a robust design, although some uncertainties regarding long-term outcomes remain.
Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding treatment effect duration and cost-effectiveness estimates, the context of high unmet need and the potential for significant patient benefit mitigate these concerns.
